What is the Eli Lilly memory drug? A Look at Kisunla (Donanemab)
•
3 min read
In July 2024, the U.S. Food and Drug Administration (FDA) approved donanemab, also known as Kisunla, for the treatment of early symptomatic Alzheimer's disease. If you are wondering **what is the Eli Lilly memory drug**, Kisunla represents a significant advancement by targeting the underlying pathology of the disease rather than just managing symptoms.
